Payment overview · 2025
General Payments
$1,717.67
97 reported records · 21 companies
Healthcare provider profile · identity verified
Stephen Daniel Conrad, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · MARION, IN · NPI 1346735370
Verified facts
What the public records show
CMS Open Payments records show Stephen Daniel Conrad, NP received $1,717.67 in general payments during 2025 across 97 reported records.
ABBVIE INC. accounted for 23.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Caplyta, Rexulti, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Trelegy Ellipta by this doctor in 2024.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Caplyta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Caplyta as an associated drug or biological on 11 records involving 9 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Caplyta by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $401.38 | 23.4% | 23 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $255.84 | 14.9% | 22 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $156.21 | 9.1% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $131.43 | 7.7% | 7 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $121.19 | 7.1% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $88.78 | 5.2% | 4 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $78.47 | 4.6% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $54.57 | 3.2% | 3 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $50.34 | 2.9% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $50.19 | 2.9% | 2 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $49.34 | 2.9% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $47.54 | 2.8% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $43.41 | 2.5% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $40.24 | 2.3% | 2 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $30.07 | 1.8% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $24.95 | 1.4% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $23.22 | 1.4% | 1 | 2025 |
| Noven Therapeutics, LLC | Unresolved — no canonical attribution shown | $19.81 | 1.1% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $19.03 | 1.1% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $16.51 | 1.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.15 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,455.26 | 78 |
| Education | $262.41 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $255.84 | 22 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $166.14 | 9 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $156.21 | 8 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $139.11 | 6 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $121.19 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $96.13 | 8 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $86.13 | 7 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $66.90 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $66.63 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $54.95 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $54.57 | 3 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $50.34 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $50.19 | 2 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $49.34 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $47.54 | 3 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $40.24 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $32.22 | 2 | 2025 |
Source payment records
|
|||||
| VIVITROL Normalized: vivitrol |
Drug | Alkermes, Inc. | $30.07 | 1 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $24.95 | 1 | 2025 |
Source payment records
|
|||||
| PEDIARIX Normalized: pediarix |
Biological | GlaxoSmithKline, LLC. | $23.58 | 1 | 2025 |
Source payment records
|
|||||
| ROTARIX Normalized: rotarix |
Biological | GlaxoSmithKline, LLC. | $23.58 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $21.88 | 1 | 2025 |
Source payment records
|
|||||
| Secuado Normalized: secuado |
Drug | Noven Therapeutics, LLC | $19.81 | 1 | 2025 |
Source payment records
|
|||||
| Xelstrym Normalized: xelstrym |
Drug | Noven Therapeutics, LLC | $19.81 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $19.03 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.66 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.66 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $16.51 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $15.73 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CAPLYTA caplyta |
2025 | Caplyta | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 55 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
108 | 16 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference |
2025 | CAPLYTA open payments reported associated product |
CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | Caplyta open payments reported associated product |
CMS Open Payments — General Payments 11 supporting records · 9 recipient NPIs · example record 1174547314 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
118 | 26 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
96 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 802 | 165 |
| Amlodipine Besylate | Amlodipine Besylate | 510 | 102 |
| Metformin Hcl | Metformin Hcl | 413 | 74 |
| Omeprazole | Omeprazole | 379 | 68 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 377 | 82 |
| Lisinopril | Lisinopril | 352 | 69 |
| Gabapentin | Gabapentin | 336 | 59 |
| Levothyroxine Sodium | Levothyroxine Sodium | 247 | 37 |
| Losartan Potassium | Losartan Potassium | 237 | 55 |
| Fluticasone Propionate | Fluticasone Propionate | 229 | 74 |
| Hydrochlorothiazide | Hydrochlorothiazide | 206 | 39 |
| Furosemide | Furosemide | 199 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 195 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 193 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 171 | 37 |
| Meloxicam | Meloxicam | 146 | 31 |
| Jardiance | Empagliflozin | 143 | 23 |
| Famotidine | Famotidine | 127 | 27 |
| Potassium Chloride | Potassium Chloride | 126 | 24 |
| Ibuprofen | Ibuprofen | 122 | 20 |
| Ozempic | Semaglutide | 118 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 116 | 27 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 113 | 25 |
| Sertraline Hcl | Sertraline Hcl | 112 | 32 |
| Pregabalin | Pregabalin | 108 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 108 | 16 |
| Glipizide Er | Glipizide | 104 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 101 | 21 |
| Eliquis | Apixaban | 96 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 95 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 93 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 85 | 21 |
| Carvedilol | Carvedilol | 84 | 20 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 82 | 14 |
| Topiramate | Topiramate | 81 | 16 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 80 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 79 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 76 | 24 |
| Montelukast Sodium | Montelukast Sodium | 75 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 75 | 16 |
| Prednisone | Prednisone | 74 | 43 |
| Clonidine Hcl | Clonidine Hcl | 72 | 13 |
| Metformin Hcl Er | Metformin Hcl | 69 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 69 | 16 |
| Allopurinol | Allopurinol | 66 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 60 | 15 |
| Ondansetron Odt | Ondansetron | 60 | 19 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 58 | suppressed |
| Nystatin | Nystatin | 58 | 17 |
| Trulicity | Dulaglutide | 57 | suppressed |
| Bupropion Xl | Bupropion Hcl | 56 | 13 |
| Rexulti | Brexpiprazole | 55 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 55 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 54 | suppressed |
| Mounjaro | Tirzepatide | 54 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 52 | 11 |
| Alprazolam | Alprazolam | 51 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 50 | 13 |
| Rybelsus | Semaglutide | 50 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 49 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 49 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 48 | 11 |
| Methocarbamol | Methocarbamol | 47 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 47 | suppressed |
| Clonazepam | Clonazepam | 46 | suppressed |
| Simvastatin | Simvastatin | 45 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 44 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | 15 |
| Promethazine Hcl | Promethazine Hcl | 44 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 43 | 13 |
| Naproxen | Naproxen | 43 | suppressed |
| Spironolactone | Spironolactone | 43 | 12 |
| Fluconazole | Fluconazole | 41 | 26 |
| Vilazodone Hcl | Vilazodone Hcl | 41 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 38 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 38 | suppressed |
| Ezetimibe | Ezetimibe | 37 | 12 |
| Levetiracetam | Levetiracetam | 37 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 37 | suppressed |
| Linzess | Linaclotide | 36 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 35 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 34 | 29 |
| Januvia | Sitagliptin Phosphate | 33 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 33 | suppressed |
| Glipizide | Glipizide | 32 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 32 | suppressed |
| Baclofen | Baclofen | 31 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 31 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 31 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 31 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Atenolol | Atenolol | 29 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 29 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 29 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 28 | 19 |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 11 |
| Varenicline Tartrate | Varenicline Tartrate | 28 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 27 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | suppressed |
| Azithromycin | Azithromycin | 26 | 23 |
| Acyclovir | Acyclovir | 25 | suppressed |
| Lacosamide | Lacosamide | 25 | suppressed |
| Lubiprostone | Lubiprostone | 25 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 17 |
| Tresiba Flextouch U-200 | Insulin Degludec | 25 | suppressed |
| Valsartan | Valsartan | 25 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 22 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Vraylar | Cariprazine Hcl | 22 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 19 | suppressed |
| Cephalexin | Cephalexin | 19 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 19 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 19 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 17 | suppressed |
| Lactulose | Lactulose | 17 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 17 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 14 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 13 | suppressed |
| Cimetidine | Cimetidine | 13 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 13 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 13 | suppressed |
| Niacin Er | Niacin | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Caplyta | Lumateperone Tosylate | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Quviviq | Daridorexant Hcl | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | 11 |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Levetiracetam Er | Levetiracetam | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,717.67 · 97 records | ABBVIE INC. | AIRSUPRA, AREXVY, Auvelity, BEXSERO, BEYFORTUS, CAPLYTA, Cologuard Collection Kit, Dexcom G6 Transmitter, FANAPT, HETLIOZ, Korlym, MAVYRET, NURTEC ODT, PEDIARIX, QULIPTA, Qelbree, REXULTI, ROTARIX, SHINGRIX, SPRAVATO, Secuado, TONMYA, The Cologuard Plus Collection Kit, UBRELVY, VIVITROL, VRAYLAR, Veozah, Xelstrym, ZAVZPRET | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Caplyta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error